FDA
-
-
-
-
-
-
-
Vaxart gets $29M BARDA funding to advance COVID pill vaccine data
-
-
-
-
-
-
-
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
-
-
-
-
-
-
-
Vaxart Appoints Jeroen Grasman as Chief Financial Officer
-
-
-
-
-
-
-
Vaxart (VXRT) Appoints Kevin Finney to its Board
-
-
-
-
-
-
-
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
-
327,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

